ORIGINAL INVESTIGATIONS

Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension







Analysis From the Dallas Heart Study

Danielle Tientcheu, MD,* Colby Ayers, MS,* Sandeep R. Das, MD, MPH,* Darren K. McGuire, MD, MHSc,* James A. de Lemos, MD,* Amit Khera, MD, MS,* Norman Kaplan, MD,* Ronald Victor, MD,† Wanpen Vongpatanasin, MD*

JACC JOURNAL CME

This article has been selected as the month's *JACC* Journal CME activity, available online at http://www.acc.org/jacc-journals-cme by selecting the CME tab on the top navigation bar.

Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this Journal-based CME activity for a maximum of 1 $AMA\ PRA\ Category\ 1\ Credit(s)$. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation and Receipt of CME Certificate

To obtain credit for \emph{JACC} CME, you must:

- 1. Be an ACC member or JACC subscriber.
- Carefully read the CME-designated article available online and in this issue of the journal.
- Answer the post-test questions. At least 2 out of the 3 questions provided must be answered correctly to obtain CME credit.
- 4. Complete a brief evaluation.
- Claim your CME credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME Objective for This Article: After reading this article, the reader should be able to: 1) identify the presence of masked hypertension (MH)

and white-coat hypertension (WCH); 2) discuss the relationship between MH and WCH and target organ complication and cardiovascular events; 3) discuss the prevalence of MH and WCH; and 4) discuss the upper limit of normal home blood pressure (BP).

CME Editor Disclosure: *JACC* CME Editor Ragavendra R. Baliga, MD, FACC, has reported that he has no financial relationships or interests to disclose.

Author Disclosures: Dr. Vongpatanasin is supported by the University of Texas Southwestern O'Brien Kidney Center and the Kaplan Chair in Hypertension Research. Dr. Victor is supported by the National Center for Advancing Translational Sciences, UCLA Clinical and Translational Science Institute (grant UL1TR000124), the Lincy Foundation, and the Burns and Allen Chair in Cardiology Research. The DHS was funded by the Donald W. Reynolds Foundation and was partially supported by award UL1TR001105 from the National Center for Advancing Translational Sciences of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Print (article only); online (article and quiz).

CME Term of Approval

Issue Date: November 17/24, 2015 Expiration Date: November 16, 2016

Listen to this manuscript's audio summary by JACC Editor-in-Chief Dr. Valentin Fuster.



From the *Cardiology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; and the †Hypertension Center, Cedars-Sinai Heart Institute, Los Angeles, California. Dr. Vongpatanasin is supported by the University of Texas Southwestern O'Brien Kidney Center and the Kaplan Chair in Hypertension Research. Dr. Victor is supported by the National Center for Advancing Translational Sciences, UCLA Clinical and Translational Science Institute (grant UL1TR000124), the Lincy Foundation, and the Burns and Allen Chair in Cardiology Research. The DHS was funded by the Donald W. Reynolds Foundation and was partially supported by award UL1TR001105 from the National Center for Advancing Translational Sciences of the National Institutes of Health. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Manuscript received May 27, 2015; revised manuscript received September 4, 2015, accepted September 4, 2015.

Target Organ Complications and Cardiovascular Events Associated With Masked Hypertension and White-Coat Hypertension

Analysis From the Dallas Heart Study

ABSTRACT

BACKGROUND Multiple epidemiological studies from Europe and Asia have demonstrated increased cardiovascular risks associated with isolated elevation of home blood pressure (BP) or masked hypertension (MH). Previous studies have not addressed cardiovascular outcomes associated with MH and white-coat hypertension (WCH) in the general population in the United States.

OBJECTIVES The goal of this study was to determine hypertensive target organ damage and adverse cardiovascular outcomes associated with WCH (high clinic BP, \geq 140/90 mm Hg; normal home BP, <135/85 mm Hg), MH (high home BP, \geq 135/85 mm Hg; normal clinic BP, <140/90 mm Hg), and sustained hypertension (high home and clinic BP) in the DHS (Dallas Heart Study), a large, multiethnic, probability-based population cohort.

METHODS Associations among WCH, MH, sustained hypertension, and aortic pulsed wave velocity by magnetic resonance imaging; urinary albumin-to-creatinine ratio; and cystatin C were evaluated at study baseline. Then, associations between WCH and MH with incident cardiovascular outcomes (coronary heart disease, stroke, atrial fibrillation, heart failure, and cardiovascular death) over a median follow-up period of 9 years were assessed.

RESULTS The study cohort comprised 3,027 subjects (50% African Americans). The sample-weighted prevalence rates of WCH and MH were 3.3% and 17.8%, respectively. Both WCH and MH were independently associated with increased aortic pulsed wave velocity, cystatin C, and urinary albumin-to-creatinine ratio. Both WCH (adjusted hazard ratio: 2.09; 95% confidence interval: 1.05 to 4.15) and MH (adjusted hazard ratio: 2.03; 95% confidence interval: 1.36 to 3.03) were independently associated with higher cardiovascular events compared with the normotensive group, even after adjustment for traditional cardiovascular risk factors.

CONCLUSIONS In a multiethnic U.S. population, both WCH and MH were independently associated with increased aortic stiffness, renal injury, and incident cardiovascular events. Because MH is common and associated with an adverse cardiovascular profile, home BP monitoring should be routinely performed among U.S. adults. (J Am Coll Cardiol 2015;66:2159-69) © 2015 by the American College of Cardiology Foundation.

ome blood pressure (BP) monitoring has been endorsed in many hypertension guidelines as part of standard care to guide hypertension treatment, as it has been widely recognized that clinic BP may not accurately reflect out-of-office BP (1-3). The pattern of discordance between home and clinic BP can be divided into 2 major categories: white-coat hypertension (WCH; elevated office BP with normal ambulatory or home BP), or masked hypertension (MH; elevated ambulatory or home BP with normal office BP) (4). The cardiovascular (CV) prognosis of WCH is controversial. Although some studies have shown increased target organ damage and CV complications in patients

with WCH (5-7), others have demonstrated similar left ventricular mass (8) and prognosis when patients with WCH were compared with a normotensive population (9). MH was shown to be associated with an increased risk for CV events in multiple populations in Europe and Asia (5,7,10-13). However, these studies included few subjects of African descent, the racial/ethnic group with the greatest burdens of hypertension and hypertensive target organ damage. Furthermore, CV risks associated with WCH and MH differed depending on the presence or absence of antihypertensive treatment (5,6). Among the treated population, MH is proposed to represent inadequately treated hypertension, whereas patients with

Download English Version:

https://daneshyari.com/en/article/5982176

Download Persian Version:

https://daneshyari.com/article/5982176

<u>Daneshyari.com</u>